Xlife Sciences AG publishes 2025 Annual Report: Strategic positioning and preparation of key capital market transactions

Ad hoc announcement pursuant to Art. 53 LR Zurich, April 28, 2026

«2025 was a year of clear strategic focus and structural execution for Xlife Sciences,» said Oliver R. Baumann, CEO of Xlife Sciences AG. «With the preparation of the business combination with Grupo Landsteiner, the positioning of key assets for international capital markets through VERAXA Biotech, and the consistent development of our portfolio, we further validated our business model and aligned it towards sustainable value creation.»

One of the most significant events in the 2025 reporting year was the signing of a binding letter of intend (LOI) with the pharmaceutical company Grupo Landsteiner. This agreement forms the basis for the planned structuring of a business combination as well as the establishment of a jointly operated, US-based joint venture.

As part of the planned transaction, twelve project companies from the Xlife Sciences AG portfolio are to be contributed to the joint venture together with Grupo Landsteiner. The objective is to build a scalable, internationally oriented life sciences platform that integrates development, industrialization, and global commercialization of the projects within a unified business model. The strategic value of the transaction amounts to approximately USD 450 million and is fully structured in shares.

Another key focus of the financial year was the positioning of VERAXA Biotech AG as a central value driver within the Xlife Sciences portfolio. The company is planning a NASDAQ listing in 2026 and addresses a highly attractive market environment with its next-generation immuno-based cancer therapies.

In vivo studies of the BiTAC platform demonstrated high efficacy in tumor control compared to existing competing products. Complementary in vitro data also indicate significantly reduced toxicity towards healthy cells, confirming an expanded therapeutic window. The planned NASDAQ listing is intended to provide access to an international investor base and to further strengthen VERAXA's global visibility.

Operationally, 2025 was marked by visible progress across the portfolio. saniva diagnostics GmbH successfully completed two clinical studies confirming the suitability of Neuromex for the early detection of Alzheimer's disease. inflamed pharma GmbH, together with Jena University Hospital, received the Lothar Späth Award 2025 for the development of the liver-specific PET tracer DAZAmed®. Firstgene Life Sciences GmbH commenced operational activities and, together with its licensing partner Hovione, is advancing the development of a tissue-specific gene therapy for the treatment of liver cancer.

• Revenue: CHF 0.28 million (2024: CHF 0.83 million)

• Earnings per share: CHF -3.76 (2024: CHF 6.00)

• Total assets: CHF 517.1 million (2024: CHF 540.4 million)

• Equity: CHF 372.1 million (2024: CHF 396.5 million)

In 2026, Xlife Sciences will focus on the execution of key transactions and defined capital market steps, as well as on M&A activities and out-licensing, for which promising discussions are already underway. Central priorities include the closing of the transaction relating to VERAXA Biotech AG as well as the implementation of the joint venture with Grupo Landsteiner. In parallel, the remaining portfolio will be selectively further developed with the clear objective of building substance and preserving additional value options.

«We would like to extend our sincere thanks to our shareholders, whose trust and long-term support form the foundation for this development,» said David L. Deck, Chairman of the Board of Directors of Xlife Sciences AG.

«We are convinced that 2026 will be a year of execution and value realization.»

The full 2025 Annual Report is available on the Xlife Sciences AG website: https://www.xlifesciences.ch/financials

Annual Shareholders Meeting 2026 26 June 2026

Half-Year Report 2026 24 September 2026

Information for investors and journalists: Xlife Sciences AG, Dr. Dennis Fink, dennis.fink@xlifesciences.ch

Xlife Sciences is a Swiss company focused as incubator and accelerator on the value development and commercialization of promising research projects from universities and other research institutions in the life sciences sector, with the aim of providing solutions for high unmet medical needs and a better quality of life. The goal is to bridge research and development to healthcare markets. Xlife Sciences takes carefully selected projects in the four areas of technological platforms, biotechnology/ therapies, medical technology, and artificial intelligence/digital health to the next stage of development and participates in their subsequent performance. For more information, visit https://www.xlifesciences.ch/

Some of the information contained in this media release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Xlife Sciences undertakes no obligation to publicly update or revise any forward-looking statements.

/3